This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Idera Pharmaceuticals Presents Data In Preclinical Models Of Lymphoma On IMO-4200, A Dual Agonist Of TLRs 7 And 8, At The American Society For Hematology Meeting

Idera Pharmaceuticals (Nasdaq: IDRA) today announced that it presented new data showing that IMO-4200, a dual agonist of Toll-like receptor (TLR) 7 and TLR8, in combination with approved cancer treatments increased antitumor activity in preclinical models of lymphoma. The presentation by Idera scientists, entitled “IMO-4200, a novel TLR7 and TLR8 dual agonist, enhances antitumor effect of ofatumumab, rituximab and cytotoxics in preclinical models of hematological malignancies”, abstract number 3724, was made at the 53 rd annual meeting of the American Society for Hematology being held in San Diego, California December 11-13, 2011.

“The data presented show that IMO-4200 provides a novel scientific rationale for the targeted immunotherapy of hematological malignancies,” said Nicola La Monica, Ph.D., VP of Biology of Idera Pharmaceuticals. “IMO-4200 has shown to potentiate the anti-cancer activity of a broad range of approved agents, including rituximab, bortezomib and ofatumumab, in preclinical models of lymphoma.”

In the data presented today, IMO-4200 was evaluated in preclinical cell-based assays and in combination with approved cancer therapy agents in mouse models of lymphoma.

  • IMO-4200 in combination with ofatumumab, an anti-CD20 antibody, resulted in:
    • improved antitumor activity
    • increased survival compared to treatment with either agent alone
    • enhancement of complement-dependent cytotoxicity, a mechanism by which ofatumumab exerts its antitumor effect
  • IMO-4200 in combination with rituximab, an anti-CD20 antibody, and fludarabine or IMO-4200 in combination with rituximab and bendamustine resulted in:
    • improved antitumor activity
    • increased survival
    • enhanced clearance of circulating tumor cells
    • greater antibody-dependent cell cytotoxicity, a mechanism by which rituximab exerts its effect

Authors of the presentation were Daqing Wang, Ph.D., Melissa Precopio, Ph.D., Michael J. Reardon, Ph.D., Tao Lan Ph.D., Jimmy X. Tang, Ekambar R. Kandimalla, Ph.D., Alice Bexon M.D., Nicola La Monica, Ph.D. and Sudhir Agrawal, D. Phil.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs